Learning multiple sclerosis immunopathogenesis from anti-CD20 therapyFeb 1, 2023·Michael Heming,Heinz Wiendl· 0 min read Cite URLTypeCommentaryPublicationProceedings of the National Academy of Sciences of the United States of AmericaLast updated on Apr 17, 2023 ← Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis. Apr 1, 2023Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry Feb 1, 2023 →